20 September 2023>: Clinical Research
Early Echocardiography and ECG Changes Following Radiotherapy in Patients with Stage II–III HER2-Positive Breast Cancer Treated with Anthracycline-Based Chemotherapy with or without Trastuzumab-Based Therapy
Radu Valeriu Toma 12ABCG , Zgura Anca 1E , Oana Gabriela Trifănescu 12A , Laurenţia Nicoleta Galeş 12D* , Antonia Ruxandra Folea 2CDEF , Loredana Stanca 3B , Liviu Bîlteanu 234ABCDEF* , Rodica M. Anghel 1ADOI: 10.12659/MSM.941754
Med Sci Monit 2023; 29:e941754
Table 2 Clinical-demographic characteristics, types of comorbidities, and their coexistence in the patients included in the study.
Variable | Age (yrs) | Weight (kg) | Body mass index (kg/m2) | Body surface area (m2) |
---|---|---|---|---|
Mean | 55.25 | 71.55 | 27.78 | 1.78 |
Range | 48.00 | 82.00 | 30.83 | 1.00 |
Minimum | 30.00 | 43.00 | 16.80 | 1.37 |
Maximum | 78.00 | 125.00 | 47.63 | 2.37 |
Variable | Value | N | % | |
Menopause | No | 18 | 28.6 | |
Yes | 45 | 71.4 | ||
BMI Groups | Underweight ( | 1 | 1.5 | |
Normal (18.5–24.9) | 20 | 29.9 | ||
Overweight (25.0–29.9) | 25 | 37.3 | ||
Obese ≥30 | 21 | 31.3 | ||
Unknown | 1 | |||
Cardiovascular (CV) diseases or diabetes mellitus/metabolic syndrome (DM/MS) | No | 27 | 42.2 | |
Yes | 37 | 57.8 | ||
CV diseases | No | 25 | 41.0 | |
Yes | 36 | 59.0 | ||
Extended CV diseases | No | 17 | 47.2 | |
Yes | 19 | 52.8 | ||
DM/MS | No | 47 | 78.3 | |
Yes | 13 | 21.7 | ||
CV disease and DM/MS coexistence | No | 25 | 67.6 | |
Yes | 12 | 32.4 | ||
Presence of inflammatory diseases | No | 53 | 82.8 | |
Yes | 11 | 17.2 | ||
Presence of several inflammatory conditions | ≤1 | 9 | 81.8 | |
>1 | 2 | 18.2 | ||
Chronic infections | No | 56 | 91.8 | |
Yes | 5 | 8.2 | ||
Thyroid disease | No | 53 | 86.9 | |
Yes | 8 | 13.1 |